HIV-1 Gag-specific T-cell receptor (HIV-1 Gag-specific TCR) (HIV-1 Gag-specific TCR)

HIV-1 Gag-specific T-cell receptors (TCRs) are specialized proteins used in adoptive cell therapy to target and eliminate cells infected with the Human Immunodeficiency Virus type 1 (HIV-1). These receptors are engineered to recognize specific epitopes of the Gag polyprotein, such as the well-characterized SL9 peptide, when presented by Major Histocompatibility Complex (MHC) class I molecules on the surface of infected cells (PubMed: 28254748). Upon binding, the TCR-T cells initiate a potent cytotoxic response, releasing perforins and granzymes to induce apoptosis in the target cell (PubMed: 31434734). This therapeutic strategy aims to overcome the limitations of the natural immune response, which often fails to control the virus due to T-cell exhaustion or viral mutation (PubMed: 18953352). The Gag protein is a preferred target because it is highly conserved and essential for viral assembly and maturation. However, challenges include the high mutational rate of HIV, which can lead to immune escape through mutations in the Gag sequence (PubMed: 23966399). Additionally, the therapy is restricted to patients carrying specific HLA alleles, such as HLA-A*02:01, limiting its broad applicability. Safety concerns include potential off-target reactivity and cytokine release syndrome, which are common risks in engineered T-cell therapies.

Other names

Gag-specific TCRHIV-1 Gag-reactive T-cell receptorSL9-specific T-cell receptorHIV-1 Gag-specific T-cell antigen receptor

Engineered T cells expressing these TCRs recognize HIV-1 Gag peptides presented by MHC class I molecules on infected cells, triggering T-cell activation, cytokine production, and direct lysis of the target cell.